Skip to main
ACAD

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 13%
Sell 0%
Strong Sell 7%

Bulls say

ACADIA Pharmaceuticals is poised for success due to its strong commercial execution with NUPLAZID and DAYBUE, as shown by the positive fourth quarter results and optimistic 2026 guidance. Furthermore, the company has a diverse pipeline with potential in various neurological and rare diseases, including Alzheimer's and Lewy body dementia. With a strong focus on diversity and inclusion, ACADIA demonstrates a commitment to a talented workforce and is well-positioned for continued growth in the future.

Bears say

ACADIA Pharmaceuticals is facing multiple risks in the form of lower estimates for Daybue, potential dilutive equity offerings, and challenges in expanding to new indications with their current therapeutic mechanisms. Though they have seen some success with NUPLAZID and DAYBUE, their clinical-stage developments and upcoming regulatory decisions are a key factor in our negative outlook on the stock. Additionally, a recent negative trend vote from the European Medicines Agency for a key drug in their pipeline could delay potential revenue opportunities. Overall, we believe the company is overvalued and poses a high level of risk.

ACADIA Pharma (ACAD) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 15 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Jun 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.